Nuvilex Scheduled to Begin Preclinical Studies in Early August
July 09 2014 - 9:00AM
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international
biotechnology company providing cell and gene therapy solutions for
the treatment of diseases, announced today that all preparations
for the commencement of its preclinical studies to determine the
effectiveness of Nuvilex's pancreatic cancer treatment in slowing
down the accumulation of ascites fluid have been completed. As
previously announced, Translational Drug Development, LLC (TD2)
will conduct the study. Ascites fluid accumulates in the abdomen
and is usually associated with the development of advanced
pancreatic and other abdominal cancers.
Austrianova Singapore is providing the live cells to be
encapsulated using Nuvilex's Cell-in-a-Box® technology, which are
capable of converting the cancer prodrug ifosfamide, along with the
prodrug itself. The live cells are expected to arrive at TD2's
facility in Scottsdale, Arizona, during the first week of August
2014. The preclinical study will commence almost immediately
after their arrival.
"Now that we have completed all preparations for the start of
the preclinical studies on the accumulation of ascites fluid in
patients with advanced pancreatic cancer, we have the opportunity
to demonstrate that our Cell-in-a-Box® technology is one of the
most diverse platform technologies to emerge in the medical field
over the past decade," said Kenneth L. Waggoner, CEO and President
of Nuvilex, "While this is our first opportunity to thoroughly
evaluate our technology in the U.S., we anticipate that the
commencement of these preclinical studies will begin to provide
validation for that belief."
Nuvilex's pancreatic cancer treatment, which combines the
Cell-in-a-Box® live-cell encapsulation technology with the
well-known anticancer drug ifosfamide, will be studied with the
expectation that it can improve the quality of life of pancreatic
cancer patients by slowing down the accumulation of ascites fluid
in the abdomen. This is a chronic condition which is common for
those having solid tumors in their abdomen. This fluid must be
removed on a periodic basis - a situation which is exceedingly
taxing on the patients.
The organs of the abdomen are contained in a sac or membrane
called the peritoneum. Normally the peritoneal cavity contains no
fluid. Metastatic cancer in the abdomen is the predominate
cause of ascites, a condition that is not just limited to
pancreatic cancer. It can be caused by many forms of cancer in the
abdomen. Because this type of ascites fluid accumulation is a
result of an abdominal cancer, the fluid itself can contain
cancerous cells, which, in turn, can "seed" at various places in
the abdomen and form new tumors.
About Nuvilex
Nuvilex (OTCQB:NVLX) is a clinical stage biotechnology company
focused on developing and preparing to commercialize treatments for
cancer and diabetes based upon a proprietary cellulose-based
live-cell encapsulation technology known as
Cell-in-a-Box®. This unique and patented technology will be
used as a platform upon which treatments for several types of
cancer, including advanced inoperable pancreatic cancer, and
diabetes are being built. Nuvilex's treatment for pancreatic cancer
involves the widely used anticancer prodrug ifosfamide, together
with encapsulated live cells, which convert ifosfamide into its
active or "cancer-killing" form. Nuvilex is also working towards
clinical trials associated with the symptoms of advanced pancreatic
cancer and other abdominal cancers.
Safe Harbor:
This press release may contain forward-looking statements
regarding Nuvilex and its future events and results that involve
inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to Nuvilex or its management, are
intended to identify forward-looking statements. Important factors,
many of which are beyond the control of Nuvilex, that could cause
actual results to differ materially from those set forth in the
forward-looking statements include Nuvilex's ability to continue as
a going concern, delays in clinical trials or flaws or defects
regarding its products, changes in relevant legislation or
regulatory requirements, uncertainty of protection of Nuvilex's
intellectual property and Nuvilex's continued ability to raise
capital. Nuvilex does not assume any obligation to update any of
these forward-looking statements.
More information about Nuvilex can be found at
www.nuvilex.com. It can also be obtained by contacting
Investor Relations.
CONTACT: Investor Relations Contacts:
Marlin Molinaro
Marmel Communications, LLC
Phone: 702.434.8692
mmolinarofc@aol.com